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Abstract: Coronavirus disease 2019 (COVID-19) is commonly associated with kidney damage, and the
angiotensin converting enzyme 2 (ACE2) receptor for SARS-CoV-2 is highly expressed in the proximal
tubule cells. Whether patients with COVID-19 present specific manifestations of proximal tubule dys-
function remains unknown. To test this, we examined a cohort of 49 patients requiring hospitalization
in a large academic hospital in Brussels, Belgium. There was evidence of proximal tubule dysfunction in
a subset of patients with COVID-19, as attested by low-molecular-weight proteinuria (70-80%), neutral
aminoaciduria (46%), and defective handling of uric acid (46%) or phosphate (19%). None of the patients
had normoglycemic glucosuria. Proximal tubule dysfunction was independent of pre-existing comorbidi-
ties, glomerular proteinuria, nephrotoxic medications or viral load. At the structural level, kidneys from
patients with COVID-19 showed prominent tubular injury, including in the initial part of the proximal
tubule, with brush border loss, acute tubular necrosis, intraluminal debris, and a marked decrease in the
expression of megalin in the brush border. Transmission electron microscopy identified particles resem-
bling coronaviruses in vacuoles or cisternae of the endoplasmic reticulum in proximal tubule cells. Among
features of proximal tubule dysfunction, hypouricemia with inappropriate uricosuria was independently
associated with disease severity and with a significant increase in the risk of respiratory failure requiring
invasive mechanical ventilation using Cox (adjusted hazard ratio 6.2, 95% CI 1.9-20.1) or competing risks
(adjusted sub-distribution hazard ratio 12.1, 95% CI 2.7-55.4) survival models. Thus, our data estab-
lish that SARS-CoV-2 causes specific manifestations of proximal tubule dysfunction and provide novel
insights into COVID-19 severity and outcome.
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CONCLUSION:
SARS-CoV-2 Causes a Specific Dysfunction 
of the Kidney Proximal Tubule
SARS-CoV-2 causes specific manifestations of PT 
dysfunction including low molecular weight 
proteinuria, neutral aminoaciduria, and defective 
handling of uric acid and phosphateWerion, Belkhir et al, 2020
49 patients with COVID-19 requiring hospitalization (Saint-Luc Academic Hospital, Brussels, Belgium)
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Association with severity 
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Features of PT dysfunction 
(i.e. defective tubular 
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• Nadir lymphocyte count, peak 
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• Invasive mechanical ventilation 
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Coronavirus disease 2019 (COVID-19) is commonly associated with kidney damage, and the 
angiotensin converting enzyme 2 (ACE2) receptor for SARS-CoV-2 is highly expressed in 
the proximal tubule cells. Whether patients with COVID-19 present specific manifestations of 
proximal tubule dysfunction remains unknown. To test this, we examined a cohort of 49 
patients requiring hospitalization in a large academic hospital in Brussels, Belgium. There 
was evidence of proximal tubule dysfunction in a subset of patients with COVID-19, as 
attested by low-molecular-weight proteinuria (70-80%), neutral aminoaciduria (46%), and 
defective handling of uric acid (46%) or phosphate (19%). None of the patients had 
normoglycemic glucosuria. Proximal tubule dysfunction was independent of pre-existing 
comorbidities, glomerular proteinuria, nephrotoxic medications or viral load. At the structural 
level, kidneys from patients with COVID-19 showed prominent tubular injury, including in 
the initial part of the proximal tubule, with brush border loss, acute tubular necrosis, 
intraluminal debris, and a marked decrease in the expression of megalin in the brush border. 
Transmission electron microscopy identified particles resembling coronaviruses in vacuoles 
or cisternae of the endoplasmic reticulum in proximal tubule cells. Among features of 
proximal tubule dysfunction, hypouricemia with inappropriate uricosuria was independently 
associated with disease severity and with a significant increase in the risk of respiratory 
failure requiring invasive mechanical ventilation using Cox (adjusted hazard ratio 6.2, 95% CI 
1.9-20.1) or competing risks (adjusted sub-distribution hazard ratio 12.1, 95% CI 2.7-55.4) 
survival models. Thus, our data establish that SARS-CoV-2 causes specific manifestations of 













The recent pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute 
respiratory syndrome coronavirus-2 (SARS-CoV-2) has major public health and economic 
impact 
1
. The clinical spectrum of COVID-19 is broad, ranging from asymptomatic carrier 
state to severe, bilateral and diffuse pneumonia, potentially leading to acute respiratory 
distress syndrome (ARDS), respiratory failure, and/or multiple organ dysfunction
2,3
. 
Identifying early manifestations of COVID-19 and patients at risk for disease progression and 
respiratory failure is of crucial importance to alleviate the major stress on healthcare systems.  
The angiotensin converting enzyme 2 (ACE2), the receptor mediating the entry of 
SARS-CoV-2 in human cells, is expressed in the lung, heart, intestine and kidney, providing a 
rationale for the systemic manifestations of the disease
4-7
. Increasing evidence suggests that 
COVID-19 may cause kidney damage, as indicated by the occurrence of proteinuria, 
hematuria and elevated serum creatinine on admission; the high incidence of acute kidney 
injury (AKI); and a spectrum of pathologic abnormalities including acute tubular necrosis, 
endothelial damage and capillary occlusions, deposition of complement complex on tubules, 
and glomerular lesions identified in autopsy reports
8-13
. Kidney damage may result from 
hemodynamic factors, dysfunctional immune responses
14
, or direct viral infection of kidney 
cells, the latter being compatible with the detection of SARS-CoV-2 mRNA and protein in 
glomerular and tubular cells
15
 and of purported viral particles in podocytes and proximal 
tubule (PT) cells
8,16-17
. However, the identification of viral particles by electron microscropy 
is challenging, as they may easily be mistaken for normal cell organelles such as the 
endoplasmic reticulum (ER), clathrin-coated vesicles, or multivesicular bodies
18-20
. 
Overall, several arguments suggest the PT may be a specific target for SARS-CoV-2 
infection. Here, we analyzed the characteristics, extent and structural correlates of PT 











hospital in Brussels, Belgium. We further investigated the association of various markers of 














The detection of proteinuria of unknown mechanism by routine analysis among ~80 % of 
patients in the early phase of the pandemic prompted us to perform specific urinalyses in 49 
patients with documented SARS-Cov-2 infection hospitalized at the Cliniques universitaires 
Saint-Luc in Brussels, Belgium, between March 31, 2020 and April 18, 2020 (Suppl. Fig. 1). 
Patients on kidney replacement therapy at the time of admission were excluded.  
Baseline characteristics of the 49 patients with specific urinalysis are presented in 
Table 1. Median age (interquartile range, IQR) at admission was 64 years (54-74) and 69% 
were males; 86% were of Caucasian and 12% of Sub-Saharan African origin. Eighteen 
percent, 47%, 20%, and 14% had a history of cardiovascular disease, hypertension, diabetes 
and chronic kidney disease, respectively. Chronic kidney disease was ascribed to 
hypertension (n=2, 29%), chronic interstitial nephritis (n = 2, 29%), nephron mass reduction 
(n=1, 14 %), or unknown origin (n=2, 29%). Forty percent were treated with a renin 
angiotensin system inhibitor. Eight percent were on chronic immunosuppressive treatment 
and another 8% on anti-cancer therapy. A detailed list of these medications is provided in 
Table 1. 
Patients were admitted a median (IQR) of 7 days (3-9) after the onset of symptoms, 
mainly with fever (80%), dyspnea (71%) and cough (59%) (Table 1). Almost all patients 
(47/49, 96%) were admitted via the emergency room. At admission, median oxygen 
saturation while breathing ambient air was 92% (87-96); highly sensitive C-reactive protein, 
105 mg/l (54-146); glomerular filtration rate estimated by the CKD-EPI equation (eGFR), 72 
ml/min/1.73 m² (54-92); and lymphocyte count, 650 per µl (500-1060). The extent of 
pulmonary lesions at admission, quantified using computed tomography
21
, was as follows: 











hospitalized in dedicated COVID-19 units (n=40, 82%), while a minority (n=9, 18%) was 
directed to a dedicated intensive care unit. During hospitalization, 48 patients (98%) received 
hydroxychloroquine and 16 (33%) immunomodulatory drugs for COVID-19. No patient was 
treated with anti-viral drugs (Table 1). The 166 patients with routine urinalysis who presented 
between February 23, 2020 and April 18, 2020 had similar baseline characteristics (Suppl. 
Table 1).  
 
Proximal tubule dysfunction in COVID-19 
Specific urinalyses, performed a median (IQR) of 9 days (3-16) after admission, assessed the 
occurrence and pattern of PT dysfunction in patients with COVID-19 (Fig. 1; Table 2; Suppl. 
Fig. 2). Among the 49 COVID-19 patients, 69% (33/49) had elevated urinary levels of β2-
microglobulin; 85% (41/48 tested), a urinary protein to creatinine ratio (UPCR) >0.2 g/g; and 
98% (46/47), a urinary albumin to protein ratio (UAPR) <0.5 (Fig. 1A and 1B; Table 2). 
Electrophoresis of urine samples from COVID-19 patients evidenced multiple protein bands 
below 70 kDa (low-molecular-weight [LMW] proteinuria), which included the vitamin D-
binding protein (DBP) and Clara cell secretory protein (CC16). These bands, which were not 
detected in healthy controls, are similar to those detected in the urine of patients with 
congenital PT dysfunction due to Dent disease, toxic acute tubular necrosis secondary to 
tenofovir, or heavy proteinuria caused by nephrotic syndrome (Fig. 1D; Suppl. Fig. 3; Suppl. 
Table 2). The prevalence of proteinuria was similar between patients without or with diabetes 
(UPCR >0.2 g/g: 84% vs 90%, P=0.64) and between patients without or with history of CKD 
(UPCR >0.2 g/g: 86% vs 83%, P=0.88). Heavy proteinuria (UPCR >2.5 g/g) was identified in 
2 patients, and one had selective albuminuria (UAPR >0.5). The first had heavy proteinuria 
months before COVID-19, suggesting unrelated kidney disease, while no past urinalysis was 











Forty-seven percent (23/49) and 56% (27/48) of the patients had hypouricemia and/or 
hypophosphatemia, respectively (Fig. 1A; Table 2). Inappropriate uricosuria (fractional 
excretion of uric acid [FEUA] >10%) was observed in 90% (18/20) of the patients with 
hypouricemia, and defective tubular handling of uric acid (hypouricemia with inappropriate 
uricosuria) was found in 46% (18/39 tested) of the cohort (Fig. 1A; Fig. 1C; Table 2). 
Hypophosphatemia with inappropriate phosphaturia (FEP >20%) was observed in 19% (6/32).  
 Aminoaciduria was detected in 6 out of 13 (46%) tested COVID-19 patients (Fig. 1A; 
Table 2), and was restricted to neutral amino acids (Fig. 1E; Suppl. Table 3), a pattern similar 
to that found in Hartnup disease, caused by recessive mutations in SCL6A19, which encodes 




. Of interest, B
0
AT1 interacts with ACE2 
6,23
, both highly expressed in PT cells of the normal human kidney (Suppl. Fig. 4A,C,D). 
Transcriptomic analysis of specific segments of the mouse nephron confirmed the enrichment 
of genes encoding for the SARS-Cov-2 receptor ACE2, its homologue TMEM27 (collectrin), 
uric acid transporter URAT1 (SLC22A12), sodium-dependent phosphate cotransporter NaPi-
IIa (SLC34A1), and B0AT1 in PT segments (Suppl. Fig. 4B). 
Three out of the 43 patients tested had positive dipstick glucosuria upon admission. 
Two of them had a history of type 2 diabetes, concomitant hyperglycemia and significant 
glucosuria (blood glucose 215 mg/dl and 331 mg/dl; and dipstick glucosuria 2+ and 4+, 
respectively), while the remaining individual had prediabetes (HbA1c 6.0%), slightly elevated 
blood glucose (127 mg/dl) and mild glucosuria (1+). In contrast with other signs of PT 
dysfunction, none of the patients in the cohort showed normoglycemic glucosuria (Table 2). 
 Altogether, these observations showed that a specific dysfunction of the PT develops 
in a subset of patients with severe forms of COVID-19, occurs early during the course of the 
disease and is characterized by LMW proteinuria, defective handling of uric acid and 












Proximal tubule dysfunction, clinical presentation, disease severity and outcomes 
To assess the potential clinical relevance of PT dysfunction in patients hospitalized with 
COVID-19, we compared the clinical presentation, disease severity and outcomes of patients 
with versus without elevated urinary β2-microglobulin, defective handling of uric acid and 
phosphate, or aminoaciduria (Suppl. Tables 4-7).  
Biological signs of PT dysfunction were not associated with demographics, disease 
presentation or severity, or viral load, estimated from real time polymerase chain reaction and 
cycle threshold (Ct) values at admission. They were also independent from comorbidities, 
medications interfering with uric acid production or with potential PT toxicity, including anti-
viral or immunomodulatory drugs (Table 1; Suppl. Table 1).  
Patients with defective handling of uric acid (i.e. hypouricemia with inappropriate 
uricosuria), who also had higher prevalence of LMW proteinuria, aminoaciduria and defective 
handling of phosphate (Suppl. Table 5), showed higher disease severity as compared with 
others. This was evidenced by a lower nadir of lymphocyte count (median [IQR]: 250 per µl 
[100-360] vs 500 per µl [280-910, P=0.006), and higher peak values of hsCRP (324 mg/dl 
[243-349] vs 126 mg/dl [51-245], P=0.002), LDH (584 IU/l [524-726] vs 394 IU/l [317-466], 
P<0.001), and D-dimers (4461 ng/ml [2098-13348) vs 1234 ng/ml [753-2827], P=0.001), in 
these patients compared to those without inappropriate uricosuria (Suppl. Table 5).  
During a median follow-up (IQR) of 44 days (31-56), 19/49 patients (39%) in the 
cohort required invasive mechanical ventilation, 14 (29%) died, 11 (22%) developed AKI; 
and 2 (4%) required kidney replacement therapy (Suppl. Fig. 1; Suppl. Table 1). 
Hypouricemia with inappropriate uricosuria was associated with a higher occurrence of 
invasive mechanical ventilation (83% vs 14%, P<0.001) and death (50% vs 14%, P=0.02) and 











normal tubular handling of uric acid (Suppl. Table 5). Time-to-event analyses using Cox 
regressions showed an independent association between defective tubular handling of uric 
acid and higher risk of invasive mechanical ventilation or death (adjusted hazard ratio [HR] 
6.2, 95% confidence interval [CI] 1.9-20.1, P=0.002). An alternative approach considering 
death and discharge from hospital as competing events confirmed the independent association 
between tubular loss of uric acid and the need for invasive mechanical ventilation (adjusted 
subdistribution HR 12.1, 95% CI 2.7-55.4, P=0.001) (Suppl. Table 8). 
 
Proximal tubule damage in kidneys of COVID-19 patients 
To characterize structural alterations associated with PT dysfunction, we analyzed 6 kidney 
autopsy samples from patients who died of COVID-19, for whom tissue samples were well-
preserved with absence of autolysis at the optical level. The patients’ age ranged between 57 
and 82 years; 4 were males; all had abnormal proteinuria and 2 developed AKI requiring 
kidney replacement therapy (Suppl. Table 9). None of the patients received anti-viral 
medications.  
Post-mortem examination of the COVID-19 kidneys showed prominent and diffuse 
PT damage in all patients, with dilation of the tubular lumen containing cellular debris, 
denuded basement membranes and major alterations of the brush border (Fig. 2A; Suppl. Fig. 
5; Suppl. Table 10). In addition to tubular lesions, erythrocyte aggregates in peritubular and/or 
glomerular capillaries were found in 5 out of the 6 patients. One patient with moderate 
proteinuria (UPCR 0.7 g/g) showed a single lesion of focal and segmental glomerulosclerosis 
(tip lesion variant). Focal infiltration of the interstitium by mononuclear cells was observed in 
2 out of the 6 patients. 
Confocal microscopy examination revealed that the expression of the multi-ligand 











membrane of PT cells, was severely decreased (~50%) in the PT cells of patients with 
COVID-19, compared to the normal kidney (Fig. 2B). The decreased expression of megalin 
contrasted with the stable (trend to increased) expression of ACE2 in PT cells of COVID-19 
kidneys (Suppl. Fig. 4A).  
Transmission electron microscopy identified particles resembling coronaviruses in 
vacuoles or cisternae of the ER in PT cells (Fig. 3). They measured between 90 and 140 nm 
and contained small dense irregular dots of 10-20 nm. Some particles were budding into the 
ER lumen, and a few had faint wisps of projections on their surfaces that contacted the 
luminal contents, not the cytoplasm. A trilaminar envelope was identified around some 
particles. Some of the particles contained few (1 to 3) crisp, dense circles of 10-15 nm. 













In this cohort of patients hospitalized for SARS-CoV-2 infection, we provide direct evidence 
that PT dysfunction develops in a subset of patients with COVID-19 and is characterized by 
LMW proteinuria, hypophosphatemia and hypouricemia due to inappropriate urinary loss of 
phosphate and uric acid, and neutral aminoaciduria. The PT dysfunction is independent from 
pre-existing kidney disease, glomerular proteinuria, viral load, or toxic medications. Defective 
tubular handling of uric acid is independently associated with disease severity and with a 
higher incidence of respiratory failure requiring mechanical ventilation. Analyses of autopsy 
kidney samples revealed tubular damage, defective expression of megalin, and presence of 
particles resembling coronaviruses in vacuoles or ER cisternae in PT cells. 
 Our data document that COVID-19 causes a specific dysfunction of the PT. The PT 
cells reabsorb a large amount of ions, solutes and LMW proteins, using specialized transport 
systems that operate in their apical membrane
24
. These transport systems include multi-ligand 
receptors such megalin, the urate transporter URAT1 (SLC22A12), the sodium-dependent 
phosphate cotransporters NaPi-IIa (SLC34A1) and NaPi-IIc (SLC34A3), and amino acid 





. Impairment of PT transport processes leads to the urinary loss of LMW 
proteins and solutes (e.g., amino acids, uric acid, phosphate), a clinical entity called renal 
Fanconi syndrome. The PT dysfunction can result from inherited disorders (e.g., Dent disease, 
Lowe syndrome, cystinosis), or be acquired (monoclonal light chains, toxins, drugs, 
autoimmune disorders)
27
. The PT dysfunction detected in patients with COVID-19 variably 
includes LMW proteinuria, aminoaciduria, and inappropriate urinary loss of uric acid and 
phosphate but not of glucose. This corresponds to a partial renal Fanconi syndrome, as 
observed in other PT disorders
24,27-29
. The molecular mechanisms accounting for such specific 











Post-mortem examination of kidneys from patients with COVID-19 showed prominent 
lesions of PT injury, including loss of brush border, cell necrosis, and intra-luminal debris, in 
line with previous reports 
16
. These lesions are associated with a ~50% reduction in the apical 
staining for megalin in PT cells. Studies in model organisms and congenital disorders 
including Donnai-Barrow syndrome, caused by mutations in the LRP2 gene coding for 
megalin, or Dent disease, caused by mutations in the CLCN5 gene coding for the endosomal 
chloride-proton exchanger ClC-5, have highlighted the critical role of megalin in the 
reabsorption of LMW ligands by PT cells
24,25,30
. Of note, alteration of megalin expression in 
patients with COVID-19 was also observed in patients with tenofovir-induced PT 
dysfunction
31
, confirming the defect is not restricted to COVID-19. Conversely, the 
expression of megalin is preserved in patients presenting acute tubular injury without overt 
PT dysfunction, related e.g. to sepsis, aminoglycosides, or hepatorenal syndrome
31
. 
The fact that PT cells highly express ACE2 suggests that they could be targeted by 
SARS-CoV-2 at an early stage of disease. The binding affinity of SARS-CoV-2 spike 
glycoprotein to ACE2 is a major determinant of disease severity
32
. Besides its role in the renin 
angiotensin system, ACE2 facilitates the trafficking of B
0
AT1 to the apical membrane
23
. 
Recent studies reported the cryo-electron microscopy structure of the full-length human 




. The aminoaciduria observed in patients with 
COVID-19 is essentially composed of neutral amino acids, similar to that encountered in 





AT1 requires ACE2 (or the related protein collectrin) for its apical targeting in epithelial 
cells, one could speculate that SARS-CoV-2 binding and entry may lead to a partial 
dysfunction of the amino acid transporter, causing mild neutral aminoaciduria. The fact that 
B
0
AT1 is not directly affected by SARS-CoV-2 explains the moderate loss in patients with 











including URAT1, caused by viral mimetics in experimental models also supports a causative 
link between infection and PT dysfunction
33
. 
SARS-CoV-2 may damage the kidney by various mechanisms, including direct viral 
infection. The presence of SARS-CoV-2 RNA and shedding of viable SARS-CoV-2 in the 
urine have been reported
34,35
. SARS-CoV-2 is able to infect human kidney organoids 
expressing ACE2 and PT cell markers, with inhibition by soluble recombinant human 
ACE2
36
. Particles resembling coronavirus have been described in kidney samples from 
autopsied COVID-19 patients
16,17,37
. Several articles have refuted this data, and these 
structures have been identified as clathrin-coated vesicles or multivesicular bodies
19,20
. The 
particles shown here are uniform in size and appearance and are of the right size (90-140 nm) 
and similar morphology to coronaviruses. They are located inside vacuoles or ER lumens and 
show faint hints of projections in contact with the vacuolar contents - not the cell cytoplasm
19
. 
Also, the particles contain dense dots (10-15 nm), forming either crisp circles or larger, 
smudgy dots, that may correspond to sections across the tube- or helix-forming of the virus 
nucleocapsid
38,39
. Of note, most dots inside these particles appear larger than nucleocapsids 
observed in properly fixed tissue cultures
38,39
. These dots are approximately the size of 
ribosomes (~20 nm); however, only arenaviruses appear to contain ribosomes and, to our 
knowledge, no normal cell structures appear like this. Alternatively, the larger-than-expected 




In cells containing these virus-like structures, the particles are more uniform in size 
than any normal cell architecture, such as secretory granules, and they do not have the solid 
dark center of dense granules. With the limitations stated above, we believe that identified 











PT cells. Because many intracellular particles can masquerade as viruses
40-41
, further analyses 
including immunoelectron microscopy are necessary to prove their identification as viruses. 
Despite the small cohort size, our observations suggest that the presence of 
hypouricemia due to impaired tubular handling of uric acid, a marker of PT dysfunction, 
associates with disease severity and outcomes, in particular the need for invasive mechanical 
ventilation. Interestingly, hypouricemia, was common and associated with poor outcome in 
patients with SARS
42
. Potential mechanisms linking PT dysfunction and respiratory failure 
may include the loss of important solutes, including uric acid, which may affect defense 
against oxidative stress and respiratory function
43
. Genetic factors regulating SARS Cov-2 
entry into host cells may also contribute to multi-organ severity in COVID-19. Of note, we 
did not observe any association between PT dysfunction and viral load, nephrotoxic 
medications or comorbidities. Finally, although almost all patients were given the drug, 
hydroxychloroquine does not cause PT toxicity. If these findings are validated, markers of PT 
dysfunction might be useful for the initial work-up of COVID-19 patients and for identifying 
patients at risk for progression to severe disease. 
The strengths of this study include the availability of a large cohort of well-
characterized patients admitted via the emergency room; standardized protocols of treatment; 
detailed characterization of PT dysfunction; outcome analysis; correlations with viral load; 
and analyses on kidney samples from patients with COVID-19. Our work also has limitations, 
including the lack of standardized characterization of PT markers in all patients at admission, 
with limited number of measurement for some markers; and the single centre design of the 
study, requiring confirmation. Although sensitivity analyses suggest that patients included in 
this study are representative of the whole cohort, the true prevalence of PT dysfunction 











In summary, SARS-CoV-2 infection causes an early and specific dysfunction of the 
kidney PT characterized by LMW proteinuria, defective tubular handling of uric acid and 
phosphate and neutral aminoaciduria. These transport defects are associated with structural 
and molecular alterations of PT cells, and detection of particles resembling coronaviruses. 
The presence of hypouricemia and inappropriate uricosuria associates with disease severity 
and outcome. These data provide novel insights into the pathophysiology of COVID-19 and 












Study design and patients 
The very first patient with COVID-19 was admitted to our hospital on February 23, 2020. All 
consecutive adult patients, admitted between February 23, 2020 and April 18, 2020, at 
Cliniques universitaires Saint- Luc (CUSL), Brussels, Belgium with a SARS-CoV2-
associated pneumonia were enrolled in a prospective registry. The diagnosis was based on a 
positive SARS-CoV2 Real-Time RT-PCR on nasopharyngeal swab or broncho-alveolar 
lavage combined with suggestive abnormalities on chest X-ray or computed tomography.  
As the number of cases exponentially increased in March 2020, 7 additional units of 
20 beds were dedicated to COVID-19 to accommodate the flux of patients. They were all 
staffed with two fellows and two senior physicians from internal medicine or a related 
discipline (pulmonology, nephrology, cardiology, hepatogastroenterology, hematology, 
oncology, geriatrics). The infectious disease specialists supervised the general management 
and provided continuous expert advice.  
As the pandemic progressed, we realized that routine urinalysis showed proteinuria of 
unknown mechanism in around 80% of patients with COVID-19 already upon admission. 
This prompted us to subsequently order specific urinalyses in 49 patients with documented 
SARS-Cov-2 infection hospitalized at the Cliniques universitaires Saint-Luc between March 
31, 2020 and April 18, 2020 (Suppl. Fig. 1). Patients on kidney replacement therapy at the 
time of admission (hemodialysis, peritoneal dialysis or kidney transplantation) were not 
included in this study. During the study period, 68 consecutive patients with SARS-Cov-2 
infection were admitted to our institution.  
The standard treatment for patients hospitalized for COVID-19 at that time included 











days in patients without contraindication, as recommended by the Belgian COVID-19 interim 
guidelines. Patients were followed until death or end of study follow-up, on May 22, 2020. 
The study was conducted in accordance with the World Medical Association’s 
Declaration of Helsinki, the Belgian law related to experiments in humans dated May 7, 2004, 
the General Data Protection Regulation 2016/679 and the Belgian law of July 30, 2018 
regarding the protection of personal data. The Ethical Review Board of Cliniques 
universitaires Saint-Luc/UCLouvain approved the study and waived the requirement to obtain 
informed consent based on the observational design.  
 
Data collection and definitions 
The following data were extracted from electronic medical records: demographics, symptoms 
at admission, unit where the patient was hospitalized first (intensive care unit versus 
conventional unit), vital signs, biological and imaging data, and outcome. We recorded 
routine biological data obtained at admission, as well as the nadir lymphocyte count, and the 
peak values for highly sensitive C-reactive protein, lactate dehydrogenase and D-dimers 
during hospitalization. Dipstick urinalysis (glucose, proteins) was performed at the time of 
admission. The frequent observation of abnormal positive dipstick proteinuria in the first 
patients prompted subsequent measurement of urinary levels of electrolytes, proteins, 
albumin, creatinine, ß2-microglobulin, and eventually amino acids for consecutive patients 
during hospitalization. Data were checked by three physicians (AW, MP, JM) and reviewed in 
collaboration with a fourth one (MJ). 
Lab measurements were performed, unless otherwise mentioned, on an automated 
Roche Cobas 8000 analyzer, equipped with modules ISE, c702, c502 and e602 (Roche 
diagnostics, Rotkreuz, ZG, Switzerland), or a UC3500 automated urine analyzer (Sysmex). 











normal of 0.3 mg/l (mean ± 2 SD in healthy subjects)
44
. In our cohort, the urinary 
concentration of β2-microglobulin closely correlated with urinary β2-microglobulin to 
creatinine ratio (Spearman’s r= 0.91, 95% CI 0.84-0.95, P<0.001). The pH of urine samples 
was >5.5, a level at which degradation of urinary β2-microglobulin does not occur
44
. 
Acute kidney injury was defined according to KDIGO, as an increase in serum 
creatinine of ≥0.3 mg/dl (26.5 µmol/l) during hospitalization
45
. Hypophosphatemia was 
defined as serum phosphate level <0.81 mmol/l and hypouricemia as a serum uric acid level 
below 2.5 mg/dl. Inappropriate uricosuria and phosphaturia were defined as FEUA >10% in 




SARS-CoV-2 polymerase chain reaction 
SARS-CoV-2 RNA detection in nasopharyngeal swabs was performed using COVID-19 
genesig
®
 Real-Time RT-PCR assay (Primerdesign Ltd, Chandler’s Ford, United Kingdom) in 
a LightCycler 480 instrument (Roche Diagnostics, Mannheim, Germany). Primers and probe 
of this assay target the RNA-dependent RNA polymerase (RdRp) gene. A test with a cycle 
threshold less than 40 was considered positive.  
 
Urine amino acids 
Aminoaciduria was analyzed only in a subset of patients because (i) it requires non-
automated, manual preparation of samples, with a potential risk of contamination for lab 
technicians; (ii) the method is labor intensive and time consuming, requiring ~270 min for 
each run, followed by additional time for data extraction. Urine amino acids were quantified 
by ion exchange chromatography with post column derivatization with Ninhydrin using a 











Biochemical Genetics laboratory (Cliniques universitaires Saint-Luc UCLouvain). Amino 
acid excretion was normalized to creatinine (in mmol/mol creat). 
 
Antibodies and reagents 
The following antibodies were used: rabbit anti-human Gc-globulin (also known as VDBP, 
A0021, Dako); mouse anti-human ACE2 (AMAB91262, Sigma); rabbit anti-human ACE2 
(AF933, R&D); rabbit anti-human AQP1 (ab2219, Millipore); sheep anti-LRP2 (gift from P. 
Verroust and R. Kozyraki, INSERM, Paris, France); rabbit anti-human UP1 (A0257, Dako); 
rabbit anti-human LMW proteins (A0126, Dako). 
 
Immunoblot 
Sodium dodecylsulfate-polyacrylamide gel electrophoresis and immunoblot were performed 
as previously described
46
. Urine samples were thawed on ice, diluted in Laemmli buffer and 
proteins separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis (7.5%, 12% 
or 16% acrylamide slabs) in non-reducing conditions. The volume of urine loaded in each 
lane was normalized for creatinine concentration. After blotting onto nitrocellulose and 
blocking, membranes were incubated overnight at 4°C with primary antibody, washed, 
incubated with peroxidase-labeled secondary antibody, and visualized with enhanced 
chemiluminescence (ECL, Pierce, Aalst, Belgium).  
 
Pathologic evaluation 
Pathologic evaluation was performed on kidney samples obtained from autopsies of 6 
COVID-19 cases. All specimens were well preserved without autolysis, and post-mortem 
interval was less than 6 hours. None of the patients received antiviral or nephrotoxic drug. 











eosin, periodic acid-Schiff, Masson trichrome and Perls staining in all cases. Stained sections 
were evaluated for the number of total and sclerotic glomeruli; extent of interstitial fibrosis 
and tubular atrophy; presence of tubular lesions; alterations of the brush border; intra-luminal 
debris; vacuolization of tubular cells, erythrocytes aggregates; glomerular lesions; and 
interstitial inflammation
16




For electron microscopy, kidney samples obtained at autopsy from 2 patients deceased from 
COVID-19 were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.3) overnight. 
After rinsing in 0.1 M cacodylate buffer, kidney samples were post-fixed in 1% osmium 
tetroxide in cacodylate buffer for 40 min at room temperature, washed, and then stained with 
aqueous uranyl acetate for 1 hour at room temperature. After dehydration through a graded 
series of ethanol, samples were infiltrated and embedded in Epon812 (Sigma, Buchs, 
Switzerland) at 60°C for 28 hours. 350-nm semi-thin sections were cut with a Leica EM FCS 
ultra-microtome (Leica Microsystem, Germany) and stained with toluidine blue, followed by 
image acquisition by a Slidescanner (Zeiss Axio Scan.Z1, Germany) using 40x Plan 
Apochromat objective and image processing with ImageJ. 60-nm ultra-thin sections were 
collected onto formvar-coated copper grids, stained with lead phosphate dilution in water, and 
analyzed in an electron microscope (Philips CM100, Philips Electron Optics, Eindhoven, The 
Netherlands) at 80kV. The sample processing and image acquisition for toluidine blue 
staining and transmission electron microscopy were performed at the Center for Microscopy 













Immunostaining was performed on formaldehyde-fixed paraffin-embedded sections of normal 
human kidney and kidney from patients with active COVID-19 using a sequential staining 
protocol as described previously
46
. Paraffin blocks were sectioned into consecutive 5-μm-
thick slices on Superfrost Plus glass slides (Thermo Fisher Scientific). Before staining, slides 
were deparaffinized in decreasing concentrations of ethanol and antigen retrieval was 
performed by incubating in sodium citrate buffer (1.8% 0.1M citric acid, 8.2% 0.1M sodium 
citrate, in distillated water, pH 6.0) in a water bath for 30 min. The sections were blocked 
with phosphate-buffered saline (PBS) containing 5% BSA, and incubated for 1 hour with 
primary antibodies. After 3 PBS rinses, fluorophore-conjugated Alexa secondary antibodies 
(Invitrogen) were applied for 30 minutes. Negative controls were performed by omitting the 
primary antibody. Sections were subsequently mounted in ProLong Gold DAPI Antifade 
reagent (Invitrogen) and analyzed on a Zeiss LSM800 confocal microscope (Carl Zeiss), 
using x20/0.8 Plan-Apochromat (Carl Zeiss). Quantitative image analysis was performed 
using Zen 2 (blue edition) software (Carl Zeiss) by randomly selecting 5 visual fields per each 
slide that included at least three to five PTs, using constant setting parameters (i.e., pinhole, 
laser power, and offset gain and detector amplification below pixel saturation). URAT1 and 
B
0
AT1 staining were obtained from the Human Protein Atlas
47
, v15.proteinatlas.org, accessed 
on May 26, 2020. 
 
Microdissection of mouse renal tubules, quantitative RT-PCR and interactome 
The segmental expression of specific markers in mouse kidney was performed as described
48
. 
Kidneys of C57BL6J mice were digested with type-2 collagenase and tubules were isolated 
manually according to the morphological differences, before lysis in RNA extraction buffer 
from RNAqueous
®
 Total RNA Isolation Kit (Invitrogen, Carlsbad, CA). Quantitative reverse 











Total RNA was extracted from segments with RNAqueous
R
 kit (Applied Biosystems, 
Life Technologies). One µg of RNA was used to perform the reverse transcriptase reaction 
with iScript
TM
 cDNA Synthesis Kit (Bio-Rad). Changes in mRNA levels of the target genes 
were determined by relative RT-qPCR with a CFX96
TM
 Real-Time PCR Detection System 
(Bio-Rad) using iQ
TM
 SYBR Green Supermix (Bio-Rad). The analyses were performed in 
duplicate with 100nM of both sense and anti-sense primers in a final volume of 20µL using 
iQ
TM
 SYBR Green Supermix (Bio-Rad). Specific primers were designed using Primer3 
(Suppl. Table 11). PCR conditions were 95°C for 3 min followed by 40 cycles of 15 sec at 
95°C, 30 sec at 60°C. The PCR products were sequenced with the BigDye terminator kit 
(Perkin Elmer Applied Biosystems, Schwerzenbach, Switzerland) using ABI3100 capillary 
sequencer (Perkin Elmer Applied Biosystems). The efficiency of each set of primers was 
determined by dilution curves (Suppl. Table 11). The relative changes in targeted genes over 
Gapdh mRNAs were calculated using the 2
-∆∆Ct
 formula.  
The connectivity network of the interactions between human SLC6A19 (B
0
AT1) and 
other proteins including the SARS-Cov-2 receptor ACE2 and the related protein TMEM27 






Results are presented as means ± SD or median (IQR) for continuous variables and as 
numbers and proportions for categorical variables. Continuous variables were expressed in 
their natural units without standardization. Comparisons between groups were performed 
using unpaired t-test, Kruskal-Wallis, or χ2 test, as appropriate. Spearman’s rank test was 
performed to assess the correlation between serum uric acid level and urinary fractional 











Time to event analyses were performed using Cox proportional hazard regressions 
(where events were defined as the need for invasive mechanical ventilation or death) and a 
competing risk approach. In the latter, the hazard ratio for invasive mechanical ventilation and 
its 95% confidence interval was estimated by including each specific PT defect and baseline 
characteristics as covariates and by considering death and discharge as competing events. 
Multivariable time to event analyses have been adapted to adjust for pre-specified relevant 
covariates including age, gender, baseline lymphocyte count, LDH and hsCRP levels. 
Collinearity between variables was quantified using variance inflation factors, and variance 
inflation factors >10 suggested excessive correlation between variables.  
All statistical analyses were performed using GraphPad Prism (version 8.0) or Stata 
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Figure 1. Proximal tubule dysfunction in patients with COVID-19. 
A. Prevalence (%) of signs of proximal tubule (PT) dysfunction in patients with active 
COVID-19. Uβ2M, urinary β2-microglobulin; UPCR, urinary protein to creatinine ratio; 
UAPR, urinary albumin to protein ratio; HypoU, hypouricemia; inappr. UAuria, inappropriate 
uricosuria; HypoP, hypophosphatemia; inappr. Puria; inappropriate phosphaturia; AAuria; 
aminoaciduria. Numbers (n) of patients tested are shown in brackets inside the bars. 
B. Distribution of urinary ß2-microglobulin (Uβ2M), urinary protein to creatinine ratio 
(UPCR) and urinary albumin to protein ratio (UAPR), and relationship between Uβ2M and 
urinary albumin to creatinine ratio in patients with COVID-19. Circles represent individual 
values and red lines medians. 
C. Inverse relationship between the lowest serum uric acid (sUA) level and fractional 
excretion of uric acid (FEUA) in patients with (grey circles) and without (open circles) 
hypouricemia. Spearman’s coefficient, r = -0.79 (95% CI -0.89, -0.63), P<0.001, n=39. 
D. Sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by Coomassie blue 
staining and immunoblot shows the presence of low-molecular weight proteins (LMWP), 
vitamin D binding protein (VDBP), and Clara cell secretory protein (CC16). Normal urine 
and urine from a patient with Dent disease (a rare inherited PT dysfunction caused by CLCN5 
mutation) are shown as controls. Molecular weights (in kDa) of the urinary proteins are 
provided. 










bars). The reference corresponds to the upper limit of normal. Individual values are 
represented by circles and bars represent the mean values. 
 
Figure 2. Proximal tubule damage in kidneys of COVID-19 patients. 
A. Pathologic scoring of kidney lesions in COVID-19. The grid summarizes pathologic 
findings on post-mortem examination in 6 patients with COVID-19 and the presence (grey) or 
absence (white) of tubular injury, brush border loss, debris in the lumen, red blood cells 
(RBC) aggregates, vacuolization of tubular cells, and glomerular (glom.) alterations. 
Representative pictures of sections from control and COVID-19 kidneys, stained with 
Periodic Acid Schiff (PAS) or Masson’s trichrome staining (MTS), show prominent tubular 











the S1 segment of the PT), shedding of cellular debris into the lumen, as well as erythrocytes 
aggregates in peritubular capillaries. M, male; F, female. Original magnification, 20x and 
40x; scale bars, 50 µm and 25 µm, on left and right pictures, respectively. 
B. Representative pictures of double immunostaining with anti-AQP1 (green channel) and 
anti-megalin (LRP2, red channel) antibodies viewed under confocal fluorescence microscopy 
in kidney sections from a control and a patient with COVID-19. Nuclei are stained with DAPI 
(blue channel). Original magnification, 20x. Bars, 50 µm. Mean fluorescence intensity 
(M.F.I.) profiles and relative maximal intensity (rel. max. int.) for LRP2 were quantified on 
cross-sectional sections of PT from 3 controls (grey) and 5 patients who died of COVID-19 
(red). Data are mean values and s.e.m. P=0.002, unpaired t-test. 
 
Figure 3. Transmission electron microscopy of particles in proximal tubule cells in a 
kidney sample of an autopsied patient deceased from COVID-19. 
A. Low magnification electron microscopy image showing numerous particles of 
approximately 90-140 nm in diameter within the lumen of rough endoplasmic reticulum 
(RER) (arrows), some of which have budded into the lumen from the cytoplasm 
(arrowheads). Inset (a) shows the budding and the stalk of a particle. Size is indicated by the 
magnification bars. 
B. Particles observed inside vacuoles formed by RER and lighter densities inside smooth ER. 
Areas seen in the lower magnification marked by dash-lined boxes are enlarged in solid-lined 
insets and are labeled correspondingly. Insets a and b are representative of numerous particles 
containing dense smudgy dots in similarly sized particles observed within RER elsewhere. In 
some particles (a), the trilaminar membrane envelope is evident. A larger vacuole (c) without 
ribosomes studding the outside and located near the Golgi apparatus contains irregularly sized 
densities and does not contain viruses. Size of the low magnification is indicated on the print; 
size in the high magnifications is the same in all insets and is indicated by the bar in a. 
C. Particles shown (similarly as in B above), at low magnification in the large image in 
dashed-lined boxes and at high magnification in solid-lined insets corresponding to the dashed 
boxes. All particles have irregular dense black dots inside, and a few (e.g., see b, e) have crisp 
small rings, possibly exact cross sections of tubular or helical structures. Size of the low 
magnification is indicated on the print; size in the high magnifications is the same in all insets 












Table 1. Baseline characteristics of the 49 patients with specific urinalysis. 
 
Demographics and comorbidities n=49 
Age, median (IQR), years 64 (54-74) 
Male gender – no. (%) 34 (69) 
Ethnicity – no. (%)  
Caucasian 42 (86) 
Sub-Saharan African 6 (12) 
Other 1 (2) 
Cardiovascular disease – no. (%) 9 (18) 
Chronic kidney disease – no. (%) 7 (14) 
Hypertension – no. (%) 23 (47) 
Diabetes – no. (%) 10 (20) 
Human immunodeficiency virus infection – no. (%) 0 (0) 
Chronic liver disease – no. (%) 1 (2) 
Chronic pulmonary disease – no. (%) 5 (12) 
Medications – no. (%)  
Allopurinol or febuxostat 4 (8) 
Angiotensin receptor blocker 10 (20) 
ACE inhibitor 10 (20) 
Chronic immunosuppressive treatment
a
 4 (8) 
Anti-cancer drugs
b
 4 (8) 
Symptoms and vitals at admission   
Duration of symptoms, median (IQR), days 7 (3-9) 
Symptoms at admission – no. (%)  
Fever 39 (80) 
Cough 29 (59) 
Dyspnea 35 (71) 
Sore throat 2 (4) 
Confusion 6 (12) 
Anosmia/agueusia 6 (12) 
Rhinitis 7 (14) 











Chest pain 4 (8) 
Admission via emergency department – no. (%) 47 (96) 
Sa02, median (IQR), % 92 (87-96) 
Systolic BP, median (IQR), mmHg 139 (126-150) 
Diastolic BP, median (IQR), mmHg 75 (69-82) 
Heart rate, median (IQR), bpm 93 (88-103) 
Lab tests and dipstick urinalysis at admission  
hsCRP, median (IQR), mg/l 105 (54-146) 
Glycemia, median (IQR), mg/dl 121 (109-146) 
Serum creatinine, median (IQR), mg/dl 1.0 (0.8-1.2) 
eGFR, median (IQR), ml/min/1.73 m2 72 (54-92) 
Serum uric acid, median (IQR), mg/dl 4.9 (3.3-5.9) 
Sodium, median (IQR), mmol/l 135 (133-138) 
Bicarbonate, median (IQR), mmol/l 23 (22-25) 
AST, median (IQR), IU/l 36 (24-53) 
ALT, median (IQR), IU/l 27 (17-46) 
Total bilirubin, median (IQR), mg/dl 0.5 (0.4-0.7) 
CK, median (IQR), IU/l 119 (74-211) 
LDH, median (IQR), IU/l 356 (279-491) 
Lymphocytes, median (IQR), n/µl 650 (500-1060) 
Platelets, median (IQR), 10^3/µl 203 (131-233) 
Dipstick proteinuria – no. (%)  
0 8/43 (19) 
1+ 13/43 (30) 
2+ 19/43 (44) 
3+ 3/43 (7) 
Computed tomography scan of the chest upon admission 
Extent of lesions on chest CT scan – no. (%)  
<10% 4/45 (9) 
10-25% 18/45 (40) 
25-50% 14/45 (31) 
>50% 9/45 (20) 











Hydroxychloroquine – no. (%) 48 (98) 
Azithromycin – no. (%) 7 (14) 
Anti-viral drugs – no. (%) 0 (0) 
Immunomodulatory drugs
c
 - no. (%) 16 (33) 
a
Chronic immunosuppressive treatment included (one or more per 
patient) ciclosporin A (1), corticosteroids (2), methotrexate (1), 
rituximab (1).
 b
Anti-cancer drugs included cyclophosphamide (1), 
doxorubicine (1), vincristine (1), venetoclax (1), cisplatin (1), and 
cytarabine (1). 
c
Immunomodulatory drugs for COVID-19 (one or more 
per patient) included corticosteroids (7), interleukin-7 (8), tocilizumab 
(1). Continuous variables are expressed as median and interquartile 
range (IQR), and categorical variables as numbers (no.) and percentages 
(%). Sa02, oxygen saturation while breathing ambient air; BP, blood 
pressure; eGFR, CKD-EPI estimated glomerular filtration rate; hsCRP, 
highly-sensitive C-reactive protein; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase; CK, creatine kinase; LDH, lactate 











Table 2. Prevalence of proximal tubule dysfunction in COVID-19. 
 
 n tested n positive (%) 
Urinary β2-microglobulin (Uβ2M) >0.30 mg/l 49 33 (67) 
Urinary protein to creatinine ratio (UPCR) >0.2 g/g 48 41 (85) 
Urinary albumin to protein ratio (UAPR) <0.5 47 46 (98) 
Hypouricemia 49 23 (47) 
With inappropriate uricosuria 39 18 (46) 
Hypophosphatemia 48 27 (56) 
With inappropriate phosphaturia 32 6 (19) 
Aminoaciduria 13 6 (46) 
LMW proteinuria on SDS-PAGE 15 10 (67) 
Normoglycemic glucosuria 43 0 (0) 
LMW, low molecular weight; SDS-PAGE, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis. Hypouricemia with inappropriate 
uricosuria, as serum uric acid <2.5 mg/dl and fractional excretion of uric acid 
>10%; and inappropriate phosphaturia as serum phosphate <0.81 mmol/l and 
a fractional excretion of phosphate >20%.  
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